Daratumumab combinations: what can we learn?
- PMID: 28838937
- DOI: 10.1182/blood-2017-07-793349
Daratumumab combinations: what can we learn?
Conflict of interest statement
Conflict-of-interest disclosure: E.K. has received honoraria from Amgen, Janssen, Genesis Pharma, and Takeda; M.A.D. has received honoraria from Amgen, Janssen, Celgene, and Takeda.
Comment on
-
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21. Blood. 2017. PMID: 28637662 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical